Business Model Breakdown
How Capricor Therapeutics Inc Makes Money
CAPR
Market Cap
$1.7B
Profit Margin
-181.7%
Employees
160
The Short Version
Capricor Therapeutics is a clinical-stage biotechnology company focused on developing novel cell and exosome-based therapeutics. Currently pre-revenue, its business model centers on developing and gaining regulatory approval for its lead product candidate, Deramiocel (CAP-1002), for the treatment of Duchenne Muscular Dystrophy (DMD). If approved, the company will generate revenue through the sale of Deramiocel, likely leveraging partnerships for distribution, to address a critical unmet medical need in the DMD patient population.
Where the Revenue Comes From
Product sales of Deramiocel (~100% of projected revenue post-approval)
Who buys: Patients with Duchenne Muscular Dystrophy (DMD), prescribed by cardiologists and neuromuscular specialists, with reimbursement primarily from health insurers and government payers.
Why It Works (Competitive Advantages)
- ✔Unique cell therapy mechanism (cardiosphere-derived cells) with broad applicability across DMD mutations.
- ✔Potential for first-in-class approval and regulatory exclusivity in certain DMD patient populations.
- ✔Focus on cardiac and skeletal muscle function, potentially offering benefits complementary to gene therapies.
Economic Moat: Narrow (Intangible Assets/IP (proprietary cell therapy technology and potential regulatory exclusivity as an orphan drug))
What Our Analysis Says
DVR Score as of June 2, 2026
Capricor Therapeutics (CAPR) maintains its high-risk, high-reward profile, with its valuation hinging primarily on the upcoming FDA PDUFA date of August 22, 2026, for Deramiocel in Duchenne Muscular Dystrophy (DMD). The multi-billion dollar TAM and Deramiocel’s unique cell therapy mechanism offer substantial 10x growth potential if approved. Despite a strong cash position of $278.6 million providing a ~2-year runway, the company remains pre-revenue with widening net losses ($33.9 million in Q1 2026), reflecting high R&D and G&A expenses. The pending regulatory decision and the unresolved legal action with NS Pharma regarding commercialization introduce significant uncertainty, but the critical catalyst remains imminent. The score reflects a consistent assessment of these factors since the last analysis.